24th week of 2022 patent applcation highlights part 27 |
Patent application number | Title | Published |
20220185805 | NOVEL COMPOUND MODULATING GSK-3 ACTIVITY - The present invention provides a novel compound of formula I, its derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for modulating GSK3 level (e.g., GSK3 (e.g., GSK3a/GSK3b or GSK3P) or CK1) hence, activity. | 2022-06-16 |
20220185806 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 - The present disclosure relates to chemical entities useful as inhibitors of Ubiquitin Specific Peptidase 30 (USP30), pharmaceutical compositions comprising the chemical entities, and methods of using the chemical entities. The chemical entities as disclosed herein can be useful in the treatment of a disease, disorder, or condition involving mitochondrial dysfunction, including neurodegenerative diseases, motor neuron diseases, metabolic disorders, and cancers, among other ailments. | 2022-06-16 |
20220185807 | CRYSTALLINE BERBERINE ASCORBATE SALT, METHODS OF PREPARATION AND APPLICATIONS THEREOF - The present disclosure relates to crystalline berberine ascorbate salts and crystalline ketone berberine adducts, which can be used in preparing pharmaceutical or dietary compositions for the treatment or prevention of bacterial infections, cardiovascular diseases or other conditions. The present disclosure also relates to methods of preparing crystalline berberine ascorbate or other berberine salts by reaction crystallization using one or more of crystalline berberine ketone adducts as a starting material. | 2022-06-16 |
20220185808 | ACYLAMINOPYRROLO-PYRIDONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF - Disclosed are a Acylaminopyrrolo-pyridone represented by general formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer, a diastereomer, a tautomer, a solvate, a polymorph, or a prodrug thereof, a preparation method therefor and use thereof in pharmacy, the definition of each group being as described in the description. | 2022-06-16 |
20220185809 | SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS - Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use. | 2022-06-16 |
20220185810 | Novel Process for the Preparation of Filgotinib and Intermediates Thereof - The present invention relates to a novel process for the preparation of filgotinib or a pharmaceutically acceptable salt and intermediates thereof which avoid Suzuki coupling reaction. | 2022-06-16 |
20220185811 | FGFR4 KINASE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF - The invention relates to an FGFR4 kinase inhibitor, and the preparation method and use thereof. The invention relates to a compound of Formula I, or a pharmaceutically acceptable salt, solvate, polymorph or tautomer thereof, and use thereof in the manufacture of a medicament for the treatment of an FGFR4 mediated disease. | 2022-06-16 |
20220185812 | INHIBITORS OF cGAS FOR TREATING AUTOINFLAMMATORY DISEASES AND CANCER METASTASIS - Tri-cyclyl nitrogen-containing heterocyclic compounds | 2022-06-16 |
20220185813 | MODULATORS OF AMPA RECEPTOR SIGNALING - The present disclosure relates to compounds of the Formula (I) which have shown utility in modulating AMPA receptor signaling and thus preventing AMPA receptor-mediated toxicity, which may find use in the treatment of diseases in which AMPA receptor activation plays a role in neurodegeneration, including the treatment of multiple sclerosis and other diseases. | 2022-06-16 |
20220185814 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS - The invention provides substituted imidazo[1,2-b]pyridazine compounds, substituted imidazo[1,5-b]pyridazine compounds, related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,2-b]pyridazine compounds described herein include substituted imidazo[1,2-b]pyridazine-3-carboxamide compounds and variants thereof. | 2022-06-16 |
20220185815 | PYRROLOPYRAZOLE DERIVATIVE - The present invention provides a low molecular compound that inhibits phosphatidylserine synthase 1 or a pharmaceutically acceptable salt thereof, a pharmaceutical containing thereof, and a therapeutic agent for cancer having a suppressed function of phosphatidylserine synthase 2. The compound represented by formula (1) or a pharmaceutically acceptable salt thereof, wherein R | 2022-06-16 |
20220185816 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE - Related are a JAK kinase inhibitor, a preparation method for same, and applications thereof in the field of medicine, related to the field of medicinal chemistry. Provided is a novel small molecule JAK inhibitor, which has the structure as represented by formula (II). The compound provides improved efficacy and safeness in preventing or treating a JAK-related indication. | 2022-06-16 |
20220185817 | IRAK4 INHIBITORS - The present application relates to chemical compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit IRAK4 and consequently have potential utility in medicine. | 2022-06-16 |
20220185818 | PYRROLOHETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE - The present application provides a pyrroloheterocyclic derivative, a preparation method therefor, and an application thereof in medicine. Specifically, the present application provides a novel pyrroloheterocyclic derivative as represented by formula (I), a preparation method therefor, a pharmaceutical composition comprising the derivative, and an application of the derivative as a therapeutic agent, particularly as an ERK inhibitor, wherein substituents in the formula have the same definitions as those in the description. | 2022-06-16 |
20220185819 | 5-ALKYLQUINAZOLINE DERIVATIVE, METHOD OF PREPARING THE SAME, AND METHOD OF USING THE SAME - A 5-methoxyquinazoline derivative compound I, having a structure represented by formula I: | 2022-06-16 |
20220185820 | BRD4 INHIBITOR COMPOUND IN SOLID FORM AND PREPARATION METHOD THEREFOR AND USE THEREOF - Disclosed are a solid form and a crystal form of a compound represented by formula (I) used as a BRD4 inhibitor, a preparation method therefor, and an application thereof in the preparation of a medicine for treating BRD4-related diseases. (I) | 2022-06-16 |
20220185821 | MUSCARINIC ACETYLCHOLINE RECEPTOR SUBTYPE 4 ANTAGONISTS IN THE TREATMENT OF ANEMIA - This disclosure generally relates to treating anemias. More specifically, the disclosure relates to use of muscarinic acetylcholine receptor subtype 4 antagonists, such as small molecule compounds, to promote self-renewal of burst forming unit erythroid (BFU-E) cells and treat anemias. | 2022-06-16 |
20220185822 | SELECTIVE LIGANDS OF HUMAN CONSTITUTIVE ANDROSTANE RECEPTOR - A structurally novel class of heterocyclic compounds of general formula I wherein L1 is heteroaryl and L2 is heteroaryl or aryl is disclosed. The novel compounds are useful in a method of prevention or treatment of a condition that is mediated by the action, or by loss of action of Constitutive androstane receptor (CAR) receptor or its endogenous ligands. The present invention provides the novel compounds for medicinal use as well as pharmaceutical composition containing the compounds. | 2022-06-16 |
20220185823 | Prevention, Prophylactic and Therapeutic Treatment of Autoimmune Diseases Including Multiple Sclerosis Using Novel Small Molecules and Compositions Thereof - The present invention relates to the prevention, prophylactic and therapeutic treatment of autoimmune diseases including but not limited to multiple sclerosis by administering novel small molecules to a subject in need thereof. | 2022-06-16 |
20220185824 | PI-CONJUGATED COMPOUND, METHOD FOR PRODUCING PI-CONJUGATED COMPOUND, INK COMPOSITION, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, LIGHT EMITTING MATERIAL, CHARGE TRANSPORT MATERIAL, LIGHT EMITTING FILM AND ORGANIC ELECTROLUMINESCENT ELEMENT - Disclosed is a π-conjugated compound that has a structure of the following Formula (1) and a HOMO level of −5.3 eV or higher, | 2022-06-16 |
20220185825 | SALT FORM AND CRYSTAL FORM OF A2A RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR - Provided are a salt form and a crystal form of adenosine A | 2022-06-16 |
20220185826 | Tandem Carbene Phosphors - Tandem carbene phosphors such as those of Formula I can act as electron acceptors in tandem to increase the energy separation between the ground and excited state, which is higher than those found in analogous monometallic complexes. These compounds should find application as luminescent materials in organic light emitting diodes (OLEDs). | 2022-06-16 |
20220185827 | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS - The invention provides a complex comprising Zn | 2022-06-16 |
20220185828 | Silylated Derivatives Of Aromatic Heterocycles - The present disclosure describes methods for silylating aromatic derivatives, comprising the use of hydrosilanes and potassium hydroxide. | 2022-06-16 |
20220185829 | Silicon-based Tetrahydrocannabinol Derivatives and Compositions Thereof - Silicon-based tetrahydrocannabinol derivatives and methods for their synthesis are provided, in which the derivatives contain a tetrahydrocannabinol molecule and at least one silicon-based group containing Si—O—Si bonds. The derivatives are useful in topical and dermatological compositions, have potential beneficial topical properties, and enhance solubility and compatibility in topical and dermatological formulations containing the silicon-based materials. | 2022-06-16 |
20220185830 | METHOD FOR PRODUCING SILANE COMPOUND - Provided is a method for producing a silane compound, which does not produce corrosive substances such as acids, does not use organic solvents and which contributes to a reduction in environmental load. This method for producing a silane compound has D) a siloxane decomposition step for heating a mixture containing: a siloxane compound A), which is a cyclic siloxane compound A-1) represented by formula (1), a linear siloxane compound A-2) represented by formula (2) and/or a silsesquioxane compound that is represented by formula (3) and has a siloxane bond as a main chain skeleton; a carbonate compound B) including at least one of a diaryl carbonate, a dialkyl carbonate and a monoalkylmonoaryl carbonate; and a basic compound catalyst C). The step D) further includes subjecting the siloxane compound A) to alkoxylation and/or aryloxylation. (In the formulae, R | 2022-06-16 |
20220185831 | STAT3 PROTEIN DEGRADERS - The present disclosure provides compounds represented by Formulae I and IV: wherein R | 2022-06-16 |
20220185832 | CD73 INHIBITORS - Disclosed are compounds that arc inhibitors of CD73 and arc useful in treating CD73-associated diseases or conditions, and compositions containing the compounds. | 2022-06-16 |
20220185833 | PROCESS FOR THE CARBONYLATION OF EPOXIDES - The invention relates to a process for the carbonylation of epoxides in the presence of catalyst systems, in which the carbonylation is carried out in the presence of carbon monoxide, and wherein the catalyst system comprises a vanadium-based, chromium-based, manganese-based and/or tungsten-based compound, preferably a tungsten-based compound. The invention further relates to carbonylation products and carbonylation conversion products and to the use of catalyst systems according to the invention for carbonylation of epoxides. | 2022-06-16 |
20220185834 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND - An organometallic compound represented by Formula 1: | 2022-06-16 |
20220185835 | SYNTHESIS AND USE OF OXA-SPIRODIPHOSPHINE LIGAND - The present invention relates to the technical field of chiral synthesis, and specifically provides the synthesis and use of a new type of oxa-spirodiphosphine ligands. The bisphosphine ligand is prepared with oxa-spirobisphenol as a starting material after triflation, palladium catalyzed coupling with diaryl phosphine oxide, reduction of trichlorosilane, further palladium catalyzed coupling with diaryl phosphine oxide, and further reduction of trichlorosilane. The oxa-spiro compound has central chirality, and thus includes L-oxa-spirodiphosphine ligand and R-oxa-spirodiphosphine ligand. The racemic spirodiphosphine ligand is capable of being synthesized from racemic oxa-spirobisphenol as a raw material. The present invention can be used as a chiral ligand in the asymmetric hydrogenation of unsaturated carboxylic acids. The complex of the ligand with ruthenium can achieve an enantioselectivity of greater than 99% in the asymmetric hydrogenation of methyl-cinnamic acid. | 2022-06-16 |
20220185836 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF CANCERS - The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one polar moiety as a ligand. | 2022-06-16 |
20220185837 | CRYSTALLINE FORMS OF LNT - The invention relates to crystalline polymorphs of lacto-N-tetraose (LNT) and methods for making the same for use in pharmaceutical compositions, nutritional formulations and food supplements. | 2022-06-16 |
20220185838 | CARBOHYDRATE LIGANDS THAT BIND TO IGM ANTIBODIES AGAINST MYELIN-ASSOCIATED GLYCOPROTEIN - The invention relates to carbohydrate ligands presenting the minimal Human Natural Killer-1 (HNK-1) epitope that bind to anti-MAG (myelin-associated glycoprotein) IgM antibodies, and their use in diagnosis as well as for the treatment of anti-MAG neuropathy. In particular, the invention relates to disaccharides of formula (I) and (II) wherein Z is optionally substituted phenyl, heteroaryl, arylcarbonyl, or heteroarylmethyl, and to therapeutically acceptable polymers comprising a multitude of substituents of formula (I) and/or formula (II), wherein Z is a bifunctional linker connecting the disaccharides to the polymer backbone. | 2022-06-16 |
20220185839 | PROCESS FOR THE MANUFACTURE OF (2S,3S,4S,5R,6S)-3,4,5-TRIHYDROXY-6-(((4AR,10AR)-7-HYDROXY-1-PROPYL-1,2,3- ,4,4A,5,10,10A-OCTAHYDROBENZO[G]QUINOLIN-6-YL)OXY)TETRAHYDRO-2H-PYRAN-2-CA- RBOXYLIC ACID - The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below and pharmaceutically acceptable salts thereof | 2022-06-16 |
20220185840 | PHARMACEUTICAL POLYMORPHS OF MOLNUPIRAVIR - The present invention provides a crystalline and an amorphous form of a Molnupiravir and methods of making the crystalline form and amorphous form of Molnupiravir. | 2022-06-16 |
20220185841 | METHOD FOR PRODUCING PEPTIDE COMPOUND, REAGENT FOR FORMING PROTECTIVE GROUP, AND HYDRAZINE DERIVATIVE - Provided are a method for producing a peptide compound including a step of using a hydrazine derivative represented by Formula (1); a reagent for forming a protective group including the compound; and a hydrazine derivative. In Formula (1), a ring A represents an aromatic hydrocarbon ring or an aromatic heterocyclic ring, R represents a hydrogen atom, an amino protective group, an amino acid residue, or a peptide residue, k represents an integer of 1 to 5, n represents 1 or 2, and R | 2022-06-16 |
20220185842 | AMINO DEPROTECTION USING 3-(DIETHYLAMINO)PROPYLAMINE - The invention provides a method for the cleavage of Fmoc group characterized by using a solution comprising 3-(diethylamino)propylamine. In particular, it provides a method for the preparation of peptides in solid phase wherein Fmoc protected amino acids are used and the Fmoc group is cleaved by a solution comprising 3-(diethylamino)propylamine. | 2022-06-16 |
20220185843 | PROTEIN PURIFICATION METHOD - A method is provided for purifying physiologically active proteins, especially antibodies, in order to remove impurities such as DNA contaminants and viruses with minimal loss of physiologically active proteins. The physiologically active protein is introduced into an aqueous solution of low conductivity at a pH of below the isoelectric point of the physiologically active protein to precipitate impurities as particles. The particles are removed, leaving a purified physiologically active protein. | 2022-06-16 |
20220185844 | PEPTIDE-DERIVED THERAPEUTICS TARGETING SET8 FOR THE TREATMENT OF CANCER - The present invention relates to treatment of cancer. In particular, the present invention relates to peptides that bind SET8 for the treatment of cancer. | 2022-06-16 |
20220185845 | NOVEL DEPSIPEPTIDES AND USES THEREOF - The present invention relates generally to novel depsipeptides, to methods for the preparation of the novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders. | 2022-06-16 |
20220185846 | METHODS FOR SYNTHESIZING BETA-HOMOAMINO ACIDS - Methods of making β-homoamino acids as intermediate for synthesis of peptide monmer and dimer α4β7-antagonists are disclosed. The disclosed methods include solid phase and solution phase methods. | 2022-06-16 |
20220185847 | A SUBUNIT VACCINE FOR TREATMENT OR PREVENTION OF A RESPIRATORY TRACT INFECTION - The present invention relates to modified metapneumovirus (hMPV) F proteins, stabilized in the pre-fusion conformation. It also relates to immunogenic compositions (vaccines) comprising these proteins for preventing and/or treating human subjects against respiratory tract infections. | 2022-06-16 |
20220185848 | RECOMBINANT VACCINE AGAINST MAREK'S DISEASE AND NEWCASTLE DISEASE - Provided herein are immunogenic compositions containing recombinant viruses capable of inducing protection in poultry against both Marek's disease virus (MDV) and Newcastle disease virus (NDV). Such viruses incorporate nucleic acids for expressing at least one MDV antigen, such as glycoprotein B, and antigenic portions thereof, in a recombinant NDV genome. | 2022-06-16 |
20220185849 | PROTEINS FOR THE TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERS - The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis. | 2022-06-16 |
20220185850 | PESTICIDAL GENES AND METHODS OF USE - The invention relates to the field of molecular biology and particularly novel genes that encode pesticidal proteins useful for controlling pests, particularly plant pests. These proteins and the nucleic acid sequences that encode them are useful in preparing pesticidal compositions and in the production of transgenic pest-resistant plants. | 2022-06-16 |
20220185851 | MUTANT FRAGMENTS OF OSPA AND METHODS AND USES RELATING THERETO - The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a | 2022-06-16 |
20220185852 | METHODS AND COMPOSITIONS FOR IMPROVED PRODUCTION OF AN ANTIGEN FOR USE IN AN S. AUREUS VACCINE - The present invention relates to an improved antigen derived from | 2022-06-16 |
20220185853 | AMANTADINE BINDING PROTEIN - Disclosed herein are amantadine binding polypeptides, fusion proteins thereof, and uses of such polypeptides and fusion proteins. | 2022-06-16 |
20220185854 | TFEB MUTANTS AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF DISORDERS THAT REQUIRE THE INDUCTION OF THE CELLULAR AUTOPHAGY-LYSOSOMAL SYSTEM - The invention relates to constitutively active mutants of the transcription factor TFEB, which can mutate the lysine of one or both sites of positions 219 and 347; and/or also mutate the glutamic acid of one or both sites of positions 221 and 349, in order to eliminate the SUMOylation of the protein. By replacing these residues either from positions 219 and/or 221 and/or 347 and/or 349 by any other amino acid (such as arginine or alanine), it gives rise to a mutated TFEB, which more actively induces the expression of genes and protein synthesis of the lysosomal and autophagic pathway. Such as lysosomal storage disorders, neurodegenerative diseases, liver diseases, muscle diseases and metabolic diseases, and/or disorders or processes in the aging of the skin. | 2022-06-16 |
20220185856 | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides - Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner. | 2022-06-16 |
20220185857 | FMS-LIKE TYROSINE KINASE 3 LIGAND (FLT3L)-BASED CHIMERIC PROTEINS - FMS-like tyrosine kinase 3L (FLT3L) fused to human cytokines, which find use in, e.g., cancer treatments, is described. | 2022-06-16 |
20220185858 | GENETICALLY MODIFIED IMMUNE CELL, PREPARATION METHOD THEREFOR, AND APPLICATION - Provided are a genetically modified immune cell, a preparation method therefor, and an application. The immune cell overexpresses HIL-6 and/or L-GP130. HIL-6 or L-GP130 continuous overexpression/conditionally induced overexpression in the immune cell reduces the side effects of CAR-T therapy while maintaining immune and anti-tumour effects, and has potential value in the treatment of malignant tumours and AIDS. | 2022-06-16 |
20220185859 | IL-2 MUTEINS AND USES THEREOF - The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same. | 2022-06-16 |
20220185860 | CELL SURFACE COUPLING OF NANOPARTICLES - The present disclosure is directed, in some embodiments, to methods and compositions of comprising a cell having a non-internalizing receptor, and a nanoparticle surface-modified with a ligand that binds to the non-internalizing receptor. | 2022-06-16 |
20220185861 | METHODS AND COMPOSITIONS FOR TREATING CANCER - A nucleic acid sequence is provided that encodes a chimeric protein comprising a ligand that comprises a naturally occurring or modified follicle stimulating hormone sequence, e.g., an FSHβ sequence, or fragment thereof, which ligand binds to human follicle stimulating hormone (FSH) receptor, linked to either (a) a nucleic acid sequence that encodes an extracellular hinge domain, a transmembrane domain, a co-stimulatory signaling region, and a signaling endodomain; or (b) a nucleic acid sequence that encodes a ligand that binds to NKG2D. The vector containing the nucleic acid sequence, the chimeric proteins so encoded, and modified T cells expressing the chimeric protein, as well as method of using these compositions for the treatment of FSHR-expressing cancers or tumor cells are also provided. | 2022-06-16 |
20220185862 | DNA-BINDING DOMAIN TRANSACTIVATORS AND USES THEREOF - In some aspects, the disclosure relates to recombinant adeno-associated viruses (rAAVs) comprising a nucleic acid encoding a fusion protein comprising a DNA-binding domain and a transcriptional regulator domain and methods of using the same. In some embodiments, expression of the fusion protein results in modified expression of a target gene in a cell. | 2022-06-16 |
20220185863 | COMBINATION THERAPIES - The present invention relates to, inter alia, combinations of compositions which include chimeric proteins that find use in methods for treating disease, such as immunotherapies for cancer and autoimmunity. | 2022-06-16 |
20220185864 | IMMUNOSUPPRESSIVE GLYCOFORMS OF SOLUBLE CD52 - The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has α-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function. | 2022-06-16 |
20220185865 | MHC CLASS IA OPEN CONFORMERS - The invention relates to MHC-Ia open conformers as immunomodulatory agents, particularly in the treatment or prevention of cancer. The open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-heavy chain from the MHC-Ia molecules. The open conformer further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the MHC-Ia open conformers and immune checkpoint inhibitors. | 2022-06-16 |
20220185866 | TNFRSF14 / HVEM PROTEINS AND METHODS OF USE THEREOF - In some aspects the present invention provides methods for the treatment of B-cell lymphomas. Some such methods involve administration of HVEM ectodomain polypeptides, anti-HVEM antibodies, or anti-BTLA antibodies to subjects in need thereof. Some such methods involve use of CAR T cells, such as CD19-specific CAR T cells. The present invention also provides compositions useful in such methods. These and other embodiments of the present invention and described further herein. | 2022-06-16 |
20220185867 | MODIFIED HEMOGLOBIN MOLECULES AND USES THEREOF - Compositions that include a globin, such as hemoglobin, in a relaxed state are described. Globin molecules in a relaxed state (R state) have a higher binding affinity for carbon monoxide and oxygen than globin molecules in a tense state (T state). Hemoglobin in a relaxed state can be, for example, hemoglobin that is substantially free of 2,3-diphosphoglycerate or hemoglobin that includes a β-Cys93 that is covalently modified to inhibit one or both salt bridges between β-Asp94, β-His146 and α-Lys40. Methods for using these compositions, such as for treating carbon monoxide poisoning, and methods for producing these compositions, are also disclosed. | 2022-06-16 |
20220185868 | BIOREACTOR ARRANGEMENT AND CONTINUOUS PROCESS FOR PRODUCING AND CAPTURING A BIOPOL YMER - Provided is a bioreactor arrangement for producing a biopolymer expressed by a cell and a continuous process for a capturing the biopolymer employing two chromatography units operated in series or independently. | 2022-06-16 |
20220185869 | MAMMALIAN CELL CULTURE - The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures. | 2022-06-16 |
20220185870 | HIV/HCV CROSS-REACTIVE ANTIBODIES AND USES THEREOF - The present disclosure relates to antibodies and uses thereof for treating an HIV infection, an HCV infection, or an HIV/HCV co-infection. | 2022-06-16 |
20220185871 | METHODS TO IDENTIFY IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS - The invention is directed to methods to identify improbable mutations in the heavy or light chain variable domain of an antibody, methods to identify antigens which bind to antibodies comprising such improbable mutations, and methods of using such antigens to induce immune responses. | 2022-06-16 |
20220185872 | METHOD FOR INHIBITING PLATELET DERIVED GROWTH FACTOR SIGNALING WITH C3aR OR C5aR ANTIBODIES - A method of modulating growth factor responses of cells expressing C3a receptor (C3aR) and C5a receptor (C5aR) and at least one growth factor receptor includes administering to the cells at least one agent that modulates C3aR and/or C5aR signaling of the cells. | 2022-06-16 |
20220185873 | ENGINEERED ANTIBODY FOR INHIBITION OF FIBROSIS - A chimeric, humanized or single-chain antibody contains a light chain variable region containing the complementarity determining regions of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and a heavy chain variable region containing the complementarity determining regions SEQ ID NO:5 and SEQ ID NO:6. The antibody or antibody fragment thereof is capable of binding the C-terminal telopeptide of the α2(I) chain of human collagen I, and is useful in the treatment of diseases or disorders associated with excessive collagen fibril. | 2022-06-16 |
20220185874 | NOVEL ANTI-TROPONINT ANTIBODIES - The present invention relates to an improved variant monoclonal antibody binding to cardiac troponin T and having a better K | 2022-06-16 |
20220185875 | BISPECIFIC ANTIBODY SPECIFICALLY BOUND TO VEGF AND ANG2 - The present disclosure provides a bispecific antibody specifically bound to VEGF and ANG2, comprising an anti-VEGF antibody or antigen-binding fragment thereof that specifically binds to VEGF, and an anti-ANG2 single-domain antibody that specifically binds to ANG2, wherein the anti-ANG2 single domain antibody is directly or indirectly connected to the anti-VEGF antibody or an antigen-binding fragment thereof. The present disclosure further provides an anti-ANG2 single domain antibody and an antigen-binding fragment thereof, as well as a preparation and application of said antibody. | 2022-06-16 |
20220185876 | ANTI FGF23 ANTIBODY - Antibody molecules that specifically bind to FGF23 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as FGF23-associated disorders. | 2022-06-16 |
20220185877 | ANTIBODY HEAVY CHAIN CONSTANT DOMAINS - The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same. | 2022-06-16 |
20220185878 | BIOPHARMACEUTICAL COMPOSITIONS - The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods. | 2022-06-16 |
20220185879 | IL17A Antibodies and Antagonists for Veterinary Use - Provided are various embodiments relating to anti-IL17A antibodies and IL17Ra ECD polypeptides that bind to IL17A. In various embodiments, such anti-IL17A antibodies or IL17Ra ECD polypeptides can be used in methods to treat IL17-induced conditions in subjects, such as humans or companion animals, such as canines, felines, and equines. Also provided are various embodiments relating to IgG Fc variant polypeptides having one or more amino acid substitutions for reducing binding to C1q and/or CD16. In some embodiments, the IgG Fc variants and/or polypeptides comprising the IgG Fc variants (e.g., fusion polypeptides comprising the IgG Fc variants and the anti-IL17A antibodies and/or IL17Ra ECD polypeptides described herein) may have reduced complement-mediated immune responses and/or antibody-dependent cell-mediated cytotoxicity. | 2022-06-16 |
20220185880 | ANTIBODY FOR ANTI-CLAUDIN 18A2 AND USE THEREOF - Provided in the present invention is an antibody for anti-claudin 18A2 and an immune effector cell targeting claudin 18A2. Also provided are methods for inducing cell death and treating tumours. | 2022-06-16 |
20220185881 | ANTI-CLAUDIN 18.2 ANTIBODY AND APPLICATION THEREOF - The present disclosure relates to an anti-Claudin 18.2 antibody and an application thereof. Specifically, the present invention relates to an anti-Claudin 18.2 antibody; a mouse-derived antibody, chimeric antibody, humanized antibody and antigen-binding fragment thereof which contain a CDR of the anti-Claudin 18.2 antibody, and a use thereof as a medicine. In particular, the present disclosure relates to a use of the anti-Claudin 18.2 antibody in the preparation of a drug for treating Claudin 18.2 positive diseases or disorders. | 2022-06-16 |
20220185882 | ARTIFICIAL IMMUNOSURVEILLANCE CHIMERIC ANTIGEN RECEPTOR (AI-CAR) AND CELLS EXPRESSING THE SAME - The application provides non-viral vector, comprising an artificial immunosurveillance chimeric antigen receptor (AI-CAR) expression cassette flanked by two transposons or viral terminal repeats (IR), wherein the AI-CAR expression cassette comprises an inducible gene expression unit and a CAR expression unit. | 2022-06-16 |
20220185883 | METHOD OF DETECTING TIM-3 USING ANTIBODY MOLECULES TO TIM-3 - Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders. | 2022-06-16 |
20220185884 | ANTI-CD100 ANTIBODIES AND METHODS FOR USING THE SAME - Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100. | 2022-06-16 |
20220185885 | BISPECIFIC ANTIBODY - An agent for preventing, suppressing the progression of symptoms of, suppressing the recurrence of or treating autoimmune diseases, comprising a bispecific antibody or an antibody fragment thereof, having a first arm specifically binding to PD-1 and a second arm specifically binding to CD19, as described herein. | 2022-06-16 |
20220185886 | METHODS FOR IDENTIFYING BIOMARKERS TO PREDICT TREATMENT RESPONSE - Provided are methods for treatment of cancer. Also provided are methods for treating a patient susceptible or suspected of being susceptible with anti-CD47 therapies. | 2022-06-16 |
20220185887 | HETEROMULTIMERIC PROTEINS AND METHODS OF USE THEREOF - The present application provides heteromultimeric proteins, such as bispecific antibodies, comprising a first antibody heavy chain constant domain 3 (CH3)-containing polypeptide having a substitution relative to a wildtype CH3 domain at amino acid position 354 with a bulky hydrophobic amino acid, and/or a second CH3-containing polypeptide comprising a substitution relative to a wildtype CH3 domain at ammo acid position 347 with a negatively charged amino acid residue. Also provided are polypeptides, nucleic acids and vectors encoding such polypeptides, pharmaceutical compositions, methods of preparation and methods of treatment using the heteromultimeric proteins. | 2022-06-16 |
20220185888 | DUAL SPECIFICITY POLYPEPTIDE MOLECULE - The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated viral peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof. | 2022-06-16 |
20220185889 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY PROFILING - Compositions and methods for pharmacodynamic monitoring of immunotherapy are provided herein. The compositions include an immunotherapeutic agent linked to protease substrates. Upon administration, the compositions target to sites of disease where proteases are upregulated during responsive immunotherapy and subsequently cleave the attached substrates. Cleavage fragments are detected in a sample from the body and detection of the fragments is indicative of an effect of the immunotherapeutic agent. | 2022-06-16 |
20220185890 | LAG-3 BINDING MEMBERS - The present invention relates to specific binding members which bind to lymphocyte-activation gene 3 (LAG-3). The specific binding members preferably comprise a LAG-3 antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members of the invention find application, for example, in cancer therapy. | 2022-06-16 |
20220185891 | METHODS OF ANTI-TUMOR THERAPY - The disclosure provides methods of treating a tumor in a subject in need thereof comprising administering to the subject the combination of an effective dose of a vector comprising a Fas-chimera gene operably linked to an endothelial cell-specific promoter and an effective dose of an immune checkpoint inhibitor. In some aspects of the disclosure, the immune checkpoint inhibitor is a PD-1 antagonist or PD-L1 antagonist. | 2022-06-16 |
20220185892 | Combination of Anti-LAG-3 Antibodies and Anti-PD-1 Antibodies to Treat Tumors - Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-LAG-3 antibody in combination with an anti-PD-1 antibody. | 2022-06-16 |
20220185893 | GENETICALLY ENGINEERED DUAL-TARGETING CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF - The present invention belongs to the field of genetic engineering, and particularly relates to a genetically engineered dual-targeting chimeric antigen receptor. The present invention provides a genetically engineered dual-targeting chimeric antigen receptor and a host cell thereof in response to up-regulated expression of PD-L1 in tumor cells and immune cells after these cells are exposed to malignant serosal cavity effusion. The dual-targeting chimeric antigen receptor provided by the present invention competitively binds to PD-L1 to transform an inhibition signal of PD-L1 into an activation signal and to enhance the killing activity of T cells; meanwhile, 4-1BB introduced downstream thereof can promote proliferation and survival of T cells. In addition, the present invention also discloses a host cell expressing the above dual-targeting antigen receptor and a use thereof in preventing or treating solid tumors. | 2022-06-16 |
20220185894 | BINDING MOLECULES BINDING PD-L1 AND LAG-3 - The present invention relates to antibody molecules which bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules preferably comprise a CDR-based antigen binding site for PD-L1, and a LAG-3 antigen binding site which may be located in two or more structural loops of a CH3 domain of the antibody molecule. The antibody molecules of the invention find application, for example, in cancer therapy. | 2022-06-16 |
20220185895 | METHODS OF REDUCING LARGE GRANULAR LYMPHOCYTE AND NATURAL KILLER CELL LEVELS - The present disclosure relates to methods of treating diseases or disorders associated with LGL and/or NK cells, methods of reducing or depleting LGL and/or NK cells, and methods of inducing ADCC activity using antibodies that bind to a cell surface protein on LGL and/or NK cells and comprise enhanced ADCC activity. The present invention also relates to a method of depleting or reducing the numbers of large granular lymphocytes and natural killer cells in a human subject upon administration of CD94 or CD57 or NKG2A binding molecule that consists of a part that specifically binds to the CD94 or CD57 or NKG2A receptors and an immunoglobulin Fc part. In a specific embodiment, a method of the invention depletes or reduces the number of large granular lymphocytes and natural killer cells in spleen, blood, bone marrow, joints, or other tissues. | 2022-06-16 |
20220185896 | ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF - Disclosed herein are methods for treating solid tumors (e.g., pancreatic adenocarcinoma (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC)), or Cholangiocarcinoma and others), including, but not limited to, metastatic tumors, using an anti-Galectin-9 antibody. | 2022-06-16 |
20220185897 | ANTI-AXL ANTIBODIES - Antibodies which specifically bind to the Axl protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies. | 2022-06-16 |
20220185898 | METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY - The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof. | 2022-06-16 |
20220185899 | METHODS OF INCREASING PROGRANULIN LEVELS USING ANTI-SORTILIN ANTIBODIES - The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof. | 2022-06-16 |
20220185900 | HUMAN ANTIBODIES THAT BIND RET AND METHODS OF USE THEREOF - The present invention provides fully human antibodies that bind to the RET receptor tyrosine kinase, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for treating diseases, disorders, or conditions associated with expression, activation, or signaling of the RET receptor tyrosine kinase gene, or a rearranged form thereof, including cancerous conditions and the pain associated with the cancer, or for alleviating the pain associated with other conditions attributed to, at least in part, by expression, activation or signaling of RET. The antibodies specific for RET may be useful for slowing tumor cell growth or tumor cell proliferation and also for alleviating the pain associated with the cancer and other conditions. The antibodies may also be useful for diagnosis of a disease, disorder or condition associated with RET activation or signaling. | 2022-06-16 |
20220185901 | Bispecific antibodies binding ALK-1 and BMPR-2 - The present invention relates to bispecific antibodies binding human ALK-1 and human BMPR-2. Also provided are BsABs which are agonists of ALK-1/BMPR-2 signaling, and BsABs which do not trigger osteogenic signaling. Furthermore, the invention relates to pharmaceutical uses of the BsABs, in particular for the treatment of pulmonary hypertension. Also provided are methods to screen for BsABs for use in the therapy, e.g., of pulmonary hypertension. | 2022-06-16 |
20220185902 | Antibodies That Specifically Bind To TL1A - Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis. | 2022-06-16 |
20220185903 | Novel bispecific binding molecule and drug conjugate thereof - Provided are a novel bispecific binding molecule and use thereof. The novel bispecific binding molecule-drug conjugate includes: a) a bispecific binding molecule consisting of a first binding moiety binds a tumor cell surface antigen (T) and a second antigen binding moiety binds to an internalizing effector protein (E), and b) a cytotoxic ingredient covalently conjugated to the bispecific binding molecule. The bispecific binding molecule may specifically exert cytotoxic activity against tumor cells by specifically targeting to the tumor cells through the first antigen binding moiety, and internalizing the cytotoxic ingredient into the tumor cells by the second antigen binding moiety of the bispecific binding molecule. | 2022-06-16 |
20220185904 | CD20 BINDING SINGLE DOMAIN ANTIBODIES - The present application relates, in part, to agents that bind CD20 and their use as therapeutic agents. The present application further relates to pharmaceutical compositions comprising the CD20 binding agents and their use in the treatment of various diseases. | 2022-06-16 |
20220185905 | MULTISPECIFIC AGENTS FOR TREATMENT OF CANCER - The invention provides multispecific agents having one arm binding CD47, and a second arm binding to CD24. The invention also provides multispecific agents having one arm binding to SIRPα and a second arm binding to siglec-10. | 2022-06-16 |